Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 6/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27817108 | 0.84 | HSPB1 (0.54) | HSPB1ERN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL680258 | 0.83 | HSPB1 (0.44) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL680257 | 0.83 | HSPB1 (0.44) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL23629494 | 0.80 | HSPB1 (0.41) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL23081424 | 0.78 | HSPB1 (0.44) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL29533051 | 0.77 | HSPB1 (0.72) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL15067682 | 0.77 | HSPB1 (0.72) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL20154998 | 0.75 | HSPB1 (0.53) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL29845685 | 0.75 | HSPB1 (0.53) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL16340463 | 0.74 | HSPB1 (0.67) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-04-09 | — | — | US | disclosed |
| CN-112739691-B | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3848365-A1 | TRK INHIBITOR AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-112739691-A | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | NTRK1, NTRK3, MUSK | HSPB1 940/4885ERN1 448/4885ALDH1A1 3791/4885 |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | NTRK1, NTRK3, MUSK | HSPB1 940/4885ERN1 448/4885ALDH1A1 3791/4885 |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | HSPB1 1726/4885ERN1 2134/4885ALDH1A1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.